Navigation Links
Alopecia in Medical Technology

Is Your Hair Taking a Break?

... occurred in relation to the hair loss." alopecia Areata An autoimmune form of hair loss that can affect men and women, alopecia areata, occurs when the body's white blood cells ... unpredictable from person to person. For example, alopecia areata can happen overnight or occur gradually ...

Pivotal Clinical Data Published for the Only Laser Phototherapy Device Cleared by the FDA for Hair Growth

... LaserComb in the treatment of Androgenetic alopecia in males commonly known as 'male pattern ... the treatment of certain classes of Androgenetic alopecia in males. The adverse event profile was ... treatment for hair loss caused by Androgenic alopecia in males." About the HairMax LaserComb ...

R-Tech Ueno, Ltd. Completes Phase 1 Clinical Study on RK-023

... is being developed by our company as a therapeutic drug of androgenetic alopecia (male pattern baldness; see the note below) has been completed. ... develop a drug that will become useful for the patients with androgenetic alopecia as soon as possible. Note: Androgenetic alopecia: Due to the ...

Study Finds DOXIL(R) Combination Therapy Delays Disease Progression for Patients With Metastatic Breast Cancer

... and rash (29% vs 12%) - In addition, 19% vs 52.3% reported alopecia (all grades) - Grade 3/4 hematologic ARs reported in >5% ... platelets/mm3, 61%), nausea (18%), asthenia (7%), fever (8%), alopecia (9%), vomiting (8%), diarrhea (5%), and stomatitis (5%) ...

Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine

... and fluorouracil arm (PF) had grade 3/4 neutropenia (76.9% vs. 52.5%), alopecia (11.6% vs. 0%), anemia (9.2% vs. 12.8%) and infection (6.9% vs. 6.1%). ... vs 8%), and grade 3/4 neutropenia (83% vs. 56%), dizziness (4% vs. 2%), alopecia (4% vs 1%) and diarrhea (7% vs. 3%) than those in the PF group. Patients ...

Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen

... percent), headache (43 percent), pyrexia (41 percent), myalgia (40 percent), irritability/anxiety/nervousness (33 percent), insomnia (30 percent), alopecia (28 percent), neutropenia (27 percent), nausea/vomiting (25 percent), rigors (25 percent), anorexia (24 percent), injection site reaction (23 ...

Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C

... percent), headache (43 percent), pyrexia (41 percent), myalgia (40 percent), irritability/anxiety/nervousness (33 percent), insomnia (30 percent), alopecia (28 percent), neutropenia (27 percent), nausea/vomiting (25 percent), rigors (25 percent), anorexia (24 percent), injection site reaction (23 ...

AndroScience Corporation Announces Phase 2a Study Results on ASC-J9(TM) for the Treatment of Acne

... risks and allowing for the treatment of both males and females. In addition to acne indication, AndroScience is currently pursuing androgenetic alopecia (male pattern baldness), and wound healing using topical based formulations; and prostate cancer, benign prostatic hyperplasia, and spinal bulbar ...

RAD001 Shows Potential to Reverse Resistance to Herceptin(R)* in Metastatic Breast Cancer Patients, Leading to Phase III Trial

... adverse events (greater than or equal to 10%) suspected of being related to study treatment were neutropenia, lymphopenia, stomatitis, leukopenia, alopecia and anemia. Study details: abstract #406 An open-label, multicenter Phase I trial evaluated daily RAD001 (2.5 mg, 5 mg and 10 mg) and ...

Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology

... may lead to life threatening infections), thrombocytopenia (a decrease in platelets that may result in bleeding), skin rash, flu-like symptoms or alopecia (hair loss); all of these toxicities occur frequently with many of the currently available treatments for cancer. The main side effects of ...

CHMP Recommends Approval in the European Union (EU) for New Options for Patients With Certain Primary Brain Tumors

... events in clinical studies in the Concomitant Phase (Radiotherapy + TEMODAR) and the Maintenance Phase (TEMODAR alone), respectively, were alopecia 69%, 55%; fatigue 54%, 61%; nausea 36%, 49%; vomiting 20%, 29%; anorexia 19%, 27%; headache 19%, 23%; constipation 18%, 22%; with the following ...

Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C

... site inflammation and reaction (i.e., bruise, itchiness, irritation). Injection site pain was reported in 2% of patients receiving PEGINTRON. alopecia (thinning of the hair) is also often associated with alpha interferons including PEGINTRON. Psychiatric adverse events, which include ...

New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients

... headache (43 percent), pyrexia (41 percent), myalgia (40 percent), irritability/anxiety/nervousness (33 percent), insomnia (30 percent), alopecia (28 percent), neutropenia (27 percent), nausea/vomiting (25 percent), rigors (25 percent), anorexia (24 percent), injection site reaction (23 ...

Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival

... are: flu-like symptoms, including headache, fatigue, aches and pains, fevers and chills; depression, nausea, loss of appetite and diarrhea; insomnia; alopecia (hair loss); a reaction at the site of injection; changes in blood liver function tests and in blood cell counts, including leukopenia (low white ...

Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial

... and only one patient discontinued treatment for an adverse event. Noticeably absent were toxicities common to cytotoxic chemotherapy including alopecia and myelosuppression. The Injectable Suspension product provided considerable advantages over the Injection product, including shorter time of ...

GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant)

... was maintained through repeat cycles.(2) The most commonly reported all-cause adverse events by patients receiving casopitant included neutropenia, alopecia and fatigue, and were generally balanced across treatment arms.(2) About Casopitant Casopitant is an NK-1 receptor antagonist in Phase III ...

PEGASYS(R)/COPEGUS(R) Show Benefit in Hard-to-Treat Latino Population with Hepatitis C

... in clinical trials were fatigue/asthenia (65%), headache (43%), pyrexia (41%), myalgia (40%), irritability/anxiety/nervousness (33%), insomnia (30%), alopecia (28%), neutropenia (27%), nausea/vomiting (25%), rigors (25%), anorexia (24%), injection site reaction (23%), arthralgia (22%), depression (20%), ...

Roche responds to announcement of 'IDEAL' hepatitis C trial results

... in clinical trials were fatigue/asthenia (65%), headache (43%), pyrexia (41%), myalgia (40%), irritability/anxiety/nervousness (33%), insomnia (30%), alopecia (28%), neutropenia (27%), nausea/vomiting (25%), rigors (25%), anorexia (24%), injection site reaction (23%), arthralgia (22%), depression (20%), ...

Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients

... Non-hematologic adverse events included stomatitis (10/27 patients), skin rash (10/27), diarrhea (9/27), nausea (7/27), vomiting (5/27) and alopecia (2/27). The study has shown that CPX-351 is capable of inducing marrow aplasia with few severe non-hematologic adverse events. "CPX-351 is a ...

Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium

... safety profile is distinctly different from that of most cytotoxic agents. It does not cause myelosuppression (depression of the immune system) or alopecia (hair loss) like many currently available treatments for cancer. In phase 1/2 trials it has induced tumor regressions and/or caused disease ...

Treatment with PEGASYS(R)/COPEGUS(TM) Provides Hope for Hepatitis C Patients Whose Infection Did Not Initially Respond to Peg-Intron(R)/Ribavirin

... in clinical trials were fatigue/asthenia (65%), headache (43%), pyrexia (41%), myalgia (40%), irritability/anxiety/nervousness (33%), insomnia (30%), alopecia (28%), neutropenia (27%), nausea/vomiting (25%), rigors (25%), anorexia (24%), injection site reaction (23%), arthralgia (22%), depression (20%), ...

Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks

... in clinical trials were fatigue/asthenia (65%), headache (43%), pyrexia (41%), myalgia (40%), irritability/anxiety/nervousness (33%), insomnia (30%), alopecia (28%), neutropenia (27%), nausea/vomiting (25%), rigors (25%), anorexia (24%), injection site reaction (23%), arthralgia (22%), depression (20%), ...

GSK Receives Approval for HYCAMTIN(R) (topotecan) Capsules for the Treatment of Relapsed Small Cell Lung Cancer

... The most common (>10%) non-hematologic adverse reactions (all grades) were nausea (27%), diarrhea (14%), vomiting (19%), fatigue (11%) and alopecia (10%).(2) About Small Cell Lung Cancer (SCLC)(3) SCLC is caused by an uncontrolled growth of cells beginning on the surface of the lung's breathing ...

Taxotere(R) (docetaxel) Granted FDA Approval to Treat Locally Advanced Head and Neck Cancer Prior to Chemoradiotherapy and Surgery

... with TPF had more febrile neutropenia (12% vs 7%), neutropenic infection (12% vs 8%), and grade 3/4 neutropenia (84% vs. 56%), dizziness (4% vs. 2%), alopecia (4% vs 1%) and diarrhea (7% vs. 3%) than those in the PF group. Patients in the PF group had more grade 3/4 thrombocytopenia (11% vs. 4%), stomatitis ...

Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer Treatment

... of patients with MBC were neutropenia (48%); alopecia (18%); leukopenia (11%); anemia (7%); fatigue ... (6%); creatinine elevation (5%); alopecia (1%-13%); and dyspnea (1%-7%). The most common ... events (all grades) were RBC transfusion (38%), alopecia (49%), neuropathy/sensory (29%), nausea (69%), ...

Caelyx Delays Time to Disease Progression as Maintenance Therapy in Patients with Metastatic Breast Cancer

... the CAELYX or the observation arm. The incidence of nausea/vomiting and alopecia were low and manageable; 21 percent of patients experienced grade 1 or 2 ... (a skin irritation, typically occurring on the hands and feet), rash, and alopecia (hair loss). About Schering-Plough Schering-Plough Corporation is a ...

Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C

... site inflammation and reaction (i.e., bruise, itchiness, irritation). Injection site pain was reported in 2 percent of patients receiving PEGINTRON. alopecia (thinning of the hair) is also often associated with alpha interferons including PEGINTRON. Psychiatric adverse events, which include insomnia, ...

Schering-Plough Announces Hepatitis C Data Presentations at Digestive Disease Week (DDW) 2007 Annual Meeting

... site inflammation and reaction (i.e., bruise, itchiness, irritation). Injection site pain was reported in 2 percent of patients receiving PEGINTRON. alopecia (thinning of the hair) is also often associated with alpha interferons including PEGINTRON. Psychiatric adverse events, which include insomnia, ...

Merck at ASCO 2007: New Data Demonstrate the Value of UFT as an Important Treatment Option for Patients With Metastatic Colorectal Cancer

... and, at a median follow-up of 14.9 months, the median time to progression was 8.7 months and the overall survival was 16.8 months Neurotoxicity and alopecia were minimal and there were no cases of hand–foot syndrome reported in this study. Study author, Dr. Hamid Y. Sheikh of the Christie Hospital ...

Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstrom's Macroglobulinemia

... may lead to life threatening infections), thrombocytopenia (a decrease in platelets that may result in bleeding), skin rash, flu-like symptoms or alopecia (hair loss); all of these toxicities occur frequently with many of the currently available treatments for cancer. The main side effects of perifosine ...

Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine

... to 20% included: peripheral sensory neuropathy 60% (Grade 3/4: 14%); fatigue/asthenia 50% (Grade 3/4: 14%); myalgia/arthralgia 49% (Grade 3/4: 8%); alopecia 48% (Grade 3/4: 0%); nausea 42% (Grade 3/4: 2%); stomatitis/mucositis 29% (Grade 3/4: 7%); vomiting 29% (Grade 3/4: 1%); diarrhea 22% (Grade 3/4: ...

Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology

... through prior ifosfamide (IFOS) treatment. ZIO-201 was shown to be well tolerated at the phase II dose with no significant bone marrow suppression, alopecia (hair loss) or neurotoxicity reported. Based on this encouraging data, enrollment has been expanded to include additional patients. "Ifosfamide ...
Other Contents
(Date:8/28/2014)... peer groups and clinicians is critical to the ... University of Georgia research. , A qualitative study ... determined that role models for successful breastfeeding help ... , "Mothers who received that support are more ... co-author Alex Anderson, an associate professor in the ...
(Date:8/28/2014)... compounds that could positively impact the global ... possible, thanks to researchers in Penn State,s ... suppository made from the seaweed-derived food ingredient ... Tenofovir provides a woman-initiated, drug-delivery vehicle that ... transmitted infections during unprotected heterosexual intercourse, the ...
(Date:8/28/2014)... WASHINGTON, Aug. 28, 2014A new method for measuring and ... help doctors and researchers better understand how drug abuse ... surgery and tissue engineering, and lead to better treatment ... by a team of researchers from Stony Brook University ... of Health, was published today in The Optical Society,s ...
Breaking Biology News(10 mins):Breastfeeding study shows need for effective peer counseling programs 2Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 2Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 3This is your brain's blood vessels on drugs 2This is your brain's blood vessels on drugs 3
(Date:8/29/2014)... Angeles, CA (PRWEB) August 29, 2014 ... the expert knowledge and authenticity of its doctors. ... that only the most renowned doctors in their field ... helps to assure patients have a direct link to ... Patients and doctors will be able to communicate through ...
(Date:8/29/2014)... Denver, Colorado (PRWEB) August 29, 2014 ... by Daily Gossip reveals that the new program ... , The method was created by a ... this method to overcome the disturbing problem. Manuel ... developing and using this system. , Learn ...
(Date:8/29/2014)... Colorado (PRWEB) August 29, 2014 DailyGossip.org ... This is an absolutely unique method of curing multiple ... new program was created by Dr. Gary M. Levin, ... health specialist started to become interested in alternative remedies ... that classical remedies cannot be effective in all cases ...
(Date:8/29/2014)... CA (PRWEB) August 29, 2014 Dr. ... his plan to rename his practice to Parsa Mohebi ... Restoration has served the needs of hair loss patients ... traveled to its centers in Los Angeles, Beverly Hills, ... surgical and non surgical treatments, many of which Dr. ...
(Date:8/29/2014)... (PRWEB) August 30, 2014 Developed as ... DoudouneCanadienneGoosePasCher.fr’s high quality Canada Goose products offer ... when working on Arctic runways. The company’s Canada ... jackets in the current market. Additionally, the firm has ... special offer. , At present, all high quality ...
Breaking Medicine News(10 mins):Health News:Cosmetic Town Now Advocates for the Rights of Cosmetic Patients Using Novel Approach 2Health News:Nasal Polyps Treatment Miracle Review Exposes New Natural and Permanent Healing Program 2Health News:New Natural Multiple Sclerosis Treatment Review Reveals Gary M. Levin’s Unique Cure 2Health News:US Hair Restoration Changes Name to Parsa Mohebi Hair Restoration to Better Reflect Founder 2Health News:New Designs Of Canada Goose Chilliwack Bombers From DoudouneCanadienneGoosePasCher.fr 2
Other TagsOther Tags